13th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 February 2006, Denver
This year CROI was generally an optimistic conference, with studies on new drugs, a few news studies on side effects and lipodystrophy, and a range of other interesting smaller studies. The presentation of the SMART study provided sufficient new data to restart discussions on treatment interruptions, large-scale research, and by implications, the optimal timing for initial treatment.
CROI also provides some of the best online support for people unable to attend the meeting. Abstracts are online already, and are searchable by subject or author. Webcasts are routinely provided of the plenary talks, and this year for the first time, are also provided for the most important oral scientific presentations. These online presentations, including slides, can also me downloaded as mp3 audio files or podcasts.
The 13th Conference on Retroviruses and Opportunistic Infections http://www.retroconference.org
Reports in this issue of HTB from CROI include:
- Early integrase inhibitor studies in treatment experienced patients raise hopes for new drugs in a new class
- Summary of STI studies: SMART shows clear increased risk from interrupting treatment at any CD4 count
- D:A:D study shows that PIs rather than NNRTIs drive the previously reported cardiovascular risk of combination antiretroviral therapy